Pharming Group (PHAR) has upcoming FDA regulatory milestones for Leniolisib. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by Pharming Group (PHAR).
Over the past two years, Pharming Group has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Leniolisib and RUCONEST. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Leniolisib FDA Regulatory Timeline and Events
Leniolisib is a drug developed by Pharming Group for the following indication: Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Leniolisib
- Announced Date:
- October 14, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kδ signaling.
AI Summary
Pharming reported positive topline results from a Phase II study of leniolisib in 13 people with genetically identifiable primary immunodeficiencies (PIDs) linked to altered PI3Kδ signaling. The conditions involved changes in the CTLA4, SOCS1, NFKB1 or FAS genes. Participants received treatment for 20 weeks, with the dose gradually increased.
Leniolisib was generally well-tolerated, and no new safety concerns were identified. Most evaluable participants had reduced spleen volume, with an average decrease of 26.4%; four participants with measurable lymph node lesions also showed reductions. Among participants with impaired lung gas exchange, lung function improved on average, and lung scans showed reduced disease scores in most assessed cases. Liver stiffness also improved in two of three participants who had elevated levels at the start.
The findings offer early evidence that PI3Kδ inhibition may help address immune dysregulation beyond APDS. The study was small and short, and further research is needed. All 12 participants who completed it chose to join a three-year extension study.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- September 25, 2026
- Target Action Date:
- January 30, 2027
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming announced that The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.
AI Summary
Pharming announced that the U.S. Food and Drug Administration has accepted and granted Priority Review to its supplemental application for lower doses of Joenja (leniolisib). The proposed dosing is for children aged 4 years and older who weigh between 13 and 27 kg and have activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immune disorder. If approved, Joenja could be available to eligible children weighing 13 kg or more. The FDA’s target date for a decision is January 30, 2027.
The application is supported by results from an open-label Phase III study in children aged 4 to 11. After 12 weeks, participants showed reduced lymph node enlargement and increased naive B cells—changes that suggest improvement in key signs of APDS and the underlying immune problem. Pharming also submitted scientific and clinical pharmacology assessments supporting the proposed doses for children with lower body weight. Priority Review is intended for applications that may offer important benefits for treating serious conditions.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- September 25, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
AI Summary
Pharming announced that the U.S. Food and Drug Administration has accepted and granted Priority Review to its supplemental application for lower doses of Joenja (leniolisib). The proposed dosing is for children aged 4 years and older who weigh between 13 and 27 kg and have activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immune disorder. If approved, Joenja could be available to eligible children weighing 13 kg or more. The FDA’s target date for a decision is January 30, 2027.
The application is supported by results from an open-label Phase III study in children aged 4 to 11. After 12 weeks, participants showed reduced lymph node enlargement and increased naive B cells—changes that suggest improvement in key signs of APDS and the underlying immune problem. Pharming also submitted scientific and clinical pharmacology assessments supporting the proposed doses for children with lower body weight. Priority Review is intended for applications that may offer important benefits for treating serious conditions.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- September 11, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
AI Summary
The FDA approved Pharming’s supplemental application for 40 mg and 50 mg twice-daily doses of Joenja (leniolisib) for children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS) who weigh at least 27 kg. Joenja is an oral medicine that targets the PI3Kδ pathway involved in the rare immune disorder. The approval makes it the first FDA-approved treatment for children in this age group with APDS. Pharming expects the new doses to be available in the U.S. in October through its specialty distribution and patient-support network.
The approval was supported by a Phase III study in children with APDS. After 12 weeks, participants showed improvements in enlarged lymph nodes and naïve B cells, signs of progress in the underlying immune problem. The safety profile matched earlier experience with Joenja. Reported treatment-related events were mild to moderate, and no serious events related to the drug were observed. APDS can cause repeated infections and other complications, making early treatment important for children’s health and daily lives.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- June 4, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
AI Summary
Pharming Group announced that the U.S. Food and Drug Administration has accepted its resubmitted supplemental New Drug Application for Joenja® (leniolisib). The application asks for approval of Joenja as a treatment for children ages 4 to 11 with activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare primary immunodeficiency.
Joenja is an oral medicine that works as a selective PI3Kδ inhibitor. If approved, it could give younger children with APDS another treatment option for managing this uncommon genetic immune disorder. The company said the FDA’s acceptance means the agency will review the request and continue evaluating the data supporting use in this age group.
Pharming also said it plans to submit a separate application this summer for lower doses for patients who weigh less than 27 kg.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- May 22, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group announced that the European Commission (EC) has granted marketing authorization for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older.
AI Summary
Pharming Group said the European Commission has approved Joenja (leniolisib) for adults and children age 12 and older with activated PI3K delta syndrome, or APDS. APDS is a rare primary immunodeficiency that can cause serious immune system problems. Joenja is taken by mouth and works as a selective PI3K delta inhibitor, which targets the disease’s underlying cause. The company said the approval covers all 27 European Union countries, plus Norway, Iceland, and Liechtenstein.
Experts said clinical data showed leniolisib improved important signs of immune dysregulation in APDS patients and offered a targeted option where treatment choices were limited. Pharming said it will work with healthcare providers, patient groups, and reimbursement authorities to help eligible patients get access in Europe. Joenja is already sold in the United States and the United Kingdom for APDS patients age 12 and older.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- March 27, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older.
AI Summary
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Joenja® (leniolisib) to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients 12 years and older. The CHMP recommendation advances the drug toward formal approval in the European Union for this specific, serious immune disorder.
A final decision by the European Commission is expected in about two months. If approved under exceptional circumstances, Joenja would be the first authorized treatment for APDS in the EU. The centralized marketing authorization would apply across the 27 EU Member States as well as Norway, Iceland and Liechtenstein. Leniolisib is also under regulatory review in Canada and other countries and is being studied in two Phase II trials for primary immunodeficiencies with immune dysregulation; its safety and efficacy beyond APDS have not been established.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- March 24, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) in adult and pediatric patients aged 4 years and older.
AI Summary
Pharming Group N.V. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) in adults and pediatric patients aged 4 years and older. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) evaluated the application under the Priority Review pathway after the MHLW granted Orphan Drug Designation in May 2023.
Leniolisib is also under regulatory review in the European Economic Area, Canada and several other countries. The drug is being studied in two Phase II clinical trials for primary immunodeficiencies with immune dysregulation. Regulators and investigators note that the safety and efficacy of leniolisib have not been established for immune dysregulation conditions beyond APDS, and ongoing studies will help define its broader use.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- February 1, 2026
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
AI Summary
Pharming Group announced the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
The CRL identified concerns related to clinical pharmacology and batch testing methodology. Pharming said it believes these issues can be addressed and plans to work closely with the FDA to meet the agency’s requirements. The company intends to request a Type A meeting with the FDA to discuss next steps and the path for resubmission after resolving the cited issues.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- October 1, 2025
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
AI Summary
Pharming Group N.V. said the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor designed to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). This rare primary immunodeficiency weakens the immune system and often leads to recurrent infections and serious complications.
The FDA granted Priority Review to the application and set a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026. The submission is based on positive results from a multinational Phase III study showing that 12 weeks of leniolisib reduced lymphadenopathy and increased naïve B cells, indicating correction of the underlying immune defect. It also included safety data from eight months of treatment, confirming a manageable safety profile.
If approved, leniolisib would become the first and only treatment indicated for children under 12 with APDS in the United States, offering a targeted therapy option for young patients.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- April 23, 2025
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V. announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
AI Summary
Pharming Group N.V. announced that the National Institute for Health and Care Excellence (NICE) has given positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the NHS in England and Wales. This decision marks an important milestone because Joenja® is the first and only medication approved specifically to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older. The positive recommendation followed robust Phase III clinical trial data showing that leniolisib, an oral selective PI3Kδ inhibitor, significantly improved immune deficiency and dysregulation compared to placebo. As a result, patients in England can access this breakthrough treatment immediately, while funding is expected for Wales in the coming months. This approval underlines Pharming’s commitment to offering targeted therapies for rare and progressive immunodeficiencies, aiming to enhance patient outcomes and quality of life.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- March 19, 2025
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V. announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation.
AI Summary
Pharming Group N.V. announced that the first patient has been dosed in a Phase II, proof-of-concept clinical trial using leniolisib for common variable immunodeficiency (CVID) patients with immune dysregulation. This open-label, single-arm, dose range-finding study will enroll around 20 patients aged 12 and older who have a CVID diagnosis along with evidence of lymphoproliferation and an additional clinical manifestation, such as autoimmune cytopenias, interstitial lung disease, or enteropathy. The trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of leniolisib, and explore its clinical efficacy in this patient population.
Led by Dr. Jocelyn Farmer of Beth Israel Lahey Health, the study will take place at clinical sites in the US, UK, and EU. The results from this trial are expected to guide a future Phase III program, offering a potential new treatment option for CVID patients who currently face significant unmet medical needs.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- December 11, 2024
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
AI Summary
Pharming Group N.V. announced positive topline results from its Phase III clinical trial (NCT05438407) evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). Leniolisib is an oral, selective PI3Kδ inhibitor aimed at treating this rare primary immunodeficiency. In the trial, all 21 enrolled children completed the 12-week treatment period and showed improvements in key disease markers, including a reduction in lymph node size and an increase in the fraction of naïve B cells, indicating immunophenotype correction. These findings were consistent across multiple dosing levels and built upon prior data observed in adolescent and adult APDS patients. Pharming plans to include these results in its global regulatory filings for potential approval in pediatric patients starting in 2025.
Read Announcement- Drug:
- Leniolisib
- Announced Date:
- December 11, 2024
- Indication:
- Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)
Announcement
Pharming Group N.V announced that Global regulatory filings planned to begin in 2025
AI Summary
Pharming Group N.V. announced encouraging Phase III trial results for leniolisib tablets in children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The trial data showed improvements in key markers of the disease, such as reduced lymph node size and a healthier immune cell profile, suggesting that leniolisib may address critical aspects of APDS in this younger population.
The company revealed that it plans to use the positive data from this trial as part of its global regulatory filings, which are scheduled to begin in 2025. Pharming’s strategy aims to expand treatment options for pediatric patients with APDS, a rare and serious immunodeficiency disorder, ensuring that children under 12 have access to targeted disease-modifying therapy.
Read Announcement
RUCONEST FDA Regulatory Events
RUCONEST is a drug developed by Pharming Group for the following indication: hereditary angioedema (HAE) treatment.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- RUCONEST
- Announced Date:
- October 20, 2025
- Indication:
- hereditary angioedema (HAE) treatment.
Announcement
Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10.
AI Summary
Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida, November 6–10, 2025.
Five posters will present new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibitor), highlighting its role in on-demand treatment of hereditary angioedema (HAE). These studies include indirect treatment comparisons, cost-effectiveness analyses, re-analysis of clinical data, patient-reported outcome measures, and clinician perspectives on HAE therapy trials.
Seven posters will showcase real-world evidence for Joenja® (leniolisib) in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). They feature results from a Phase III pediatric trial, infection reduction, healthcare utilization, quality of life, caregiver burden, adherence and persistence, and registry data. All ePosters will be available online and on demand for registered attendees beginning November 6.
Read Announcement